About Verastem Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.verastem.com/
Frequently Asked Questions
What is the 52-week range for VSTM?
The 52-week high is $10.82 and the 52-week low is $3.43.
What is the P/E ratio for VSTM?
The P/E ratio data is currently unavailable.
What is the dividend yield for VSTM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -165.40%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -231.59%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 10.17.
Analyst Recommendation Trends
Wall Street analyst consensus for VSTM over the last few months:
Latest VSTM News
Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026
BOSTON, October 02, 2026--New RAMP 201 Molecular Profiling and External Control Arm Analyses Supports Outcomes for Avutometinib Plus Defactinib in Recurrent LGSOC
Verastem Oncology To Present Data From New Molecular Profiling, Tumor Biomarker Analysis Of Phase 2 RAMP 201 Clinical Trial Of Avutometinib Plus Defactinib In Patients With Recurrent LGSOC, At IGCS 2026
RAMP 201 molecular profiling showed clinically meaningful activity in KRAS wild-type recurrent LGSOC, including ORRs of 22% in patients with NRAS- or BRAF-mutated tumors and 18% in patients with KRAS/NRAS/BRAF triple
Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer
BOSTON, September 28, 2026--Long-term RAMP 201 results published in Gynecologic Oncology reinforce durable clinical benefit and manageable safety profile in recurrent LGSOC.
KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
Equity Insider News Commentary - For most of the last four decades, RAS was the target oncology could not hit. That has changed quickly, and the commercial numbers are starting to follow. According to DelveInsight, the KRAS inhibitors market across the seven major markets was valued at approximately $526 million in 2025 and is projected to reach approximately $7.85 billion by 2034, a compound annual growth rate of roughly 35% over its 2024 to 2034 forecast period, with the United States expected
Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting
BOSTON, September 24, 2026--Verastem to present late-breaking oral presentation of RAMP 201 LGSOC molecular profiling and tumor biomarker analysis at IGCS 2026
Verastem Highlights Ovarian Cancer Launch, KRAS G12D Program at H.C. Wainwright
Verastem (NASDAQ:VSTM) executives outlined the company’s commercial and clinical priorities at an H.C. Wainwright event, highlighting the launch of its AVMAPKI FAKZYNJA CO-PACK for KRAS-mutated low-grade serous ovarian cancer and the advancement of its KRAS G12D inhibitor, VS-7375, across pancreatic
Wolfe Research Initiates Coverage On Verastem with Outperform Rating
Wolfe Research analyst Kalpit Patel initiates coverage on Verastem (NASDAQ:VSTM) with a Outperform rating.
HC Wainwright & Co. Reiterates Buy on Verastem, Maintains $18 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
BTIG Reiterates Buy on Verastem, Maintains $18 Price Target
BTIG analyst Jeet Mukherjee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $18 price target.
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why
VSTM shares surge 121% as Avmapki Fakzynja Co-Pack gains commercial traction and VS-7375 advances across key cancer studies.
Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers
BOSTON, September 08, 2026--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical u
Verastem Oncology To Host Investor Event On October 14 To Present Initial Efficacy And Updated Data For VS-7375 In Pancreatic, Lung, And Colorectal Cancers From Ongoing TARGET-D Clinical Development Program
Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ETVerastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-21 | Calkins Daniel | -55 | $7.7 | $424 |
| 2026-08-03 | Paterson Dan | -1,302 | $5.81 | $7,565 |
| 2026-06-22 | Paterson Dan | -20,871 | $4.18 | $87,241 |
| 2026-06-22 | Calkins Daniel | -57 | $4.13 | $235 |
| 2026-06-22 | Calkins Daniel | -4,032 | $4.18 | $16,854 |
| 2026-05-21 | BAILEY MICHAEL P | +108,000 | - | - |
| 2026-05-21 | Tollefson Karin Anna | +36,000 | - | - |
| 2026-05-21 | Stuglik Brian M | +36,000 | - | - |
| 2026-05-21 | ROBERTSON MICHELLE | +36,000 | - | - |
| 2026-05-21 | Kapur Anil | +36,000 | - | - |
| 2026-05-21 | Bunn Paul A. | +36,000 | - | - |
| 2026-05-21 | JOHNSON JOHN | +36,000 | - | - |
| 2026-05-21 | Rowinsky Eric K | +36,000 | - | - |
| 2026-05-04 | Paterson Dan | -806 | $5.82 | $4,691 |
| 2026-03-20 | Calkins Daniel | -57 | $5.74 | $327 |
| 2026-02-04 | Paterson Dan | -970 | $6.69 | $6,489 |
| 2026-01-21 | Calkins Daniel | +16,665 | - | - |
| 2026-01-21 | Paterson Dan | +213,785 | - | - |
| 2026-01-12 | Paterson Dan | -10,321 | $7.16 | $73,898 |
| 2026-01-12 | Calkins Daniel | -5,039 | $7.16 | $36,079 |
| 2026-01-06 | Kauffman Michael | +200,000 | - | - |
| 2025-12-24 | Calkins Daniel | -80 | $7.86 | $629 |
| 2025-12-16 | Stuglik Brian M | -592 | $9.14 | $5,411 |
| 2025-12-16 | Paterson Dan | -393 | $9.14 | $3,592 |
| 2025-12-16 | Gagnon Robert E. | -283 | $9.14 | $2,587 |
| 2025-12-11 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-12-10 | Paterson Dan | -2,000 | $10.07 | $20,140 |
| 2025-12-09 | Paterson Dan | -2,000 | $10.25 | $20,500 |
| 2025-12-08 | Paterson Dan | -2,000 | $10.5 | $21,000 |
| 2025-12-05 | Paterson Dan | -2,000 | $10.61 | $21,220 |
| 2025-12-04 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-12-03 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-12-02 | Paterson Dan | -2,000 | $10.32 | $20,640 |
| 2025-12-01 | Paterson Dan | -2,000 | $10.39 | $20,780 |
| 2025-11-28 | Paterson Dan | -2,000 | $10.79 | $21,580 |
| 2025-11-26 | Paterson Dan | -2,000 | $10.32 | $20,640 |
| 2025-11-25 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-11-24 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-11-21 | Bunn Paul A. | -6,250 | - | - |
| 2025-11-21 | Bunn Paul A. | +6,250 | $3.27 | $20,438 |
| 2025-11-21 | Bunn Paul A. | -6,250 | $10 | $62,500 |
| 2025-11-21 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-11-21 | Kauffman Michael | -8,550 | $10 | $85,500 |
| 2025-11-03 | Paterson Dan | -2,000 | $10 | $20,000 |
| 2025-11-03 | Paterson Dan | -1,299 | $9.35 | $12,146 |
| 2025-10-09 | Bunn Paul A. | -8,333 | $9.06 | $75,497 |